What Cencora (COR) Said on Its Q4 Earnings Call

What Cencora (COR) Said on Its Q4 Earnings Call

Cencora (NYSE:COR) reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structure that separates its specialty operations from its broader pharmaceutical distr

Cencora (COR) Q4 2026 Earnings Call Transcript

Specialty biologics now drive over half of U.S. pharmaceutical spending.

Cencora earnings rise as specialty growth reshapes 2027 outlook

Cencora earnings climb as specialty services expand. Fiscal 2027 EPS guidance, higher debt and a lower adjusted cash-flow outlook frame NYSE: COR.

Cencora beats top-line and bottom-line estimates; gives FY2027 outlook

Cencora Q4 earnings beat estimates with strong EPS and revenue growth.

Cencora Sets Fiscal 2027 Adjusted EPS Outlook at $19.40 to $19.75

The range is roughly 8% to 10% above fiscal 2026 adjusted EPS of $17.97. Excluding the assumed MWI-Covetrus merger impact, projected growth is 10% to 12%.